Lumen Bioscience develops oral antibody therapeutics.
Location: United States, Washington, Seattle
Employees: 51-200
Total raised: $16M
Founded date: 2017
Investors 1
| Date | Name | Website |
| 17.07.2021 | CARB-X | carb-x.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.09.2020 | Series B | $16M | - |
Mentions in press and media 12
| Date | Title | Description |
| 08.10.2021 | Lumen lands another DoD contract to treat Covid-related GI issues | The team at Lumen Bioscience believes that it can help patients, including those infected with Covid-19, through its plant-based drug LMN-301. Wednesday, it announced that the US Army is a believer too, handing the company de... |
| 01.09.2021 | Lumen Bioscience Launches Phase 1 Trial of Oral Biologic Drug for Preventing C. difficile Infection Recurrence | |
| 11.08.2021 | Seattle startup Lumen Bioscience is working with Google to make drugs using algae | Caitlin Gamble, head of informatics at Lumen Bioscience. (Lumen Photo) Can machine learning help spur the production of algae-based biologics? That’s the question new research from Seattle biotech startup Lumen Bioscience and Google aims to... |
| 15.07.2021 | Seattle startup Lumen Bioscience to build algae manufacturing plant in former bakery | Former bakery and future algae manufacturing site. (GeekWire Photo / Charlotte Schubert) Seattle-based biotech company Lumen Bioscience, which manufactures proteins in algae, will expand its manufacturing operations to a former bakery in th... |
| 15.07.2021 | Seattle startup Lumen Biosciences to build algae manufacturing plant in former bakery | Former bakery and future algae manufacturing site. (GeekWire Photo / Charlotte Schubert) Seattle-based biotech company Lumen Bioscience, which manufactures proteins in algae, will expand its manufacturing operations to a former bakery in th... |
| 15.07.2021 | Lumen Bioscience Expands Biologics Manufacturing Capacity with Lease of Historic Seattle Bakery | |
| 27.01.2021 | Lumen Bioscience Receives CARB-X Award to Develop Preventative for Deadly Diarrheal Diseases and Details Broad Potential of Spirulina Platform | |
| 01.09.2020 | Seattle biotech startup led by Fred Hutch, Adaptive vets raises $16M for rapid drug development tech | Lumen Chief Science Officer Jim Roberts (left) and CEO Brian Finrow. (Lumen Photo) Lumen Bioscience today announced a $16 million Series B round to help support its novel approach to rapid and low-cost drug development. The company has come... |
| 01.09.2020 | Lumen Bioscience Raises $16M in Series B Financing | Lumen Bioscience, a Seattle, WA-based clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, closed a $16m Series B financing. The round was co-led by new investor WestRiver Management and returnin... |
| 01.09.2020 | Lumen Bioscience reels in $16M Series B to 'democratize' biologics | It all started with spirulina — a nutrient-packed superfood popular on the West Coast. The photosynthetic microalgae has been commercially farmed since the 1970s. But Lumen Bioscience co-founders Brian Finrow and Jim R... |
Show more